# Neoadjuvant Biomarker ResearcH Study of Palbociclib Combined With Endocrine Therapy in Estrogen Receptor Positive/HER2 Negative Breast CAncer (NeoRHEA)

> **NCT03065621** · PHASE2 · COMPLETED · sponsor: **Jules Bordet Institute** · enrollment: 100 (actual)

## Conditions studied

- Breast Cancer Female

## Interventions

- **DRUG:** Palbociclib

## Key facts

- **NCT ID:** NCT03065621
- **Lead sponsor:** Jules Bordet Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-05
- **Primary completion:** 2019-03-28
- **Final completion:** 2023-02-01
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2023-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03065621

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03065621, "Neoadjuvant Biomarker ResearcH Study of Palbociclib Combined With Endocrine Therapy in Estrogen Receptor Positive/HER2 Negative Breast CAncer (NeoRHEA)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03065621. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*